Evidence map›Paper›PMID 40501563›Full record

ArticlebioRxiv : the preprint server for biology2025

Pancreatic cancer cachexia is mediated by PTHrP-driven disruption of adipose

Nikita Bhalerao, Yamini Ogoti, Jessica Peura, Calvin Johnson, Qingbo Chen, Ekaterina D Korobkina, Faith N Keller, Maximilian Wengyn, Robert J Norgard, Claire Shamber and 15 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Nikita BhaleraoDivision of Hematology-Oncology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Yamini OgotiDivision of Hematology-Oncology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Jessica PeuraDivision of Hematology-Oncology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Calvin JohnsonDivision of Hematology-Oncology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Qingbo ChenProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Ekaterina D KorobkinaProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Faith N KellerDepartment of Systems Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Maximilian WengynAbramson Family Cancer Research Institute and Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Robert J NorgardAbramson Family Cancer Research Institute and Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Claire ShamberDivision of Hematology-Oncology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Kelsey KluteDepartment of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Dominick DiMaioDepartment of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Karine SellinDivision of Endocrinology and Metabolism, Department of Medicine, McGill University and McGill University Health Centre, Montréal, Quebec, Canada.
Paul M GrandgenettEppley Institute for Research in Cancer and Allied Diseases, Fred and Pamela Bufferr Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
Rui LiProgram in Molecular Medicine, Diabetes Center of Excellence, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Michael A HollingsworthEppley Institute for Research in Cancer and Allied Diseases, Fred and Pamela Bufferr Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
Adilson GuilhermeProgram in Molecular Medicine, Diabetes Center of Excellence, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Michael P CzechProgram in Molecular Medicine, Diabetes Center of Excellence, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Richard KremerDivision of Endocrinology and Metabolism, Department of Medicine, McGill University and McGill University Health Centre, Montréal, Quebec, Canada.
Lihua Julie ZhuDepartment of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Jessica B SpinelliProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Emma V WatsonDepartment of Systems Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Marcus RuscettiDepartment of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.ORCID 0000-0002-4394-2087
David A GuertinProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.ORCID 0000-0003-3695-6007
Jason R PitarresiDivision of Hematology-Oncology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.

Funding

UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI James Eudy · 1985 to 2026
$55.0M
Pancreatic Cancer Detection ConsortiumU01CA210240 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Michael A. Hollingsworth · 2017 to 2026
$12.9M
CRISPR-enhanced adipocyte browning to improve glucose tolerance in obesity and diabetesR01DK130852 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI MICHAEL P CZECH · 2021 to 2026
$3.4M
Innate Immunity Training ProgramT32AI095213 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SILVERMAN, NEAL · 2011 to 2025
$2.5M
IMSD at the University of Massachusetts Medical SchoolT32GM135751 · NIGMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI BRIAN C LEWIS, Kate L Lapane · 2020 to 2026
$2.2M
Critical Resources Provided by UNMC Rapid Autopsy Program (RAP) Biorepository Stimulate Cancer ResearchR50CA211462 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Paul M Grandgenett · 2016 to 2026
$1.4M
Dissecting the oncogenic and pro-metastatic roles of PTHLH-mediated calcium signaling in pancreatic cancerR00CA252153 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI PITARRESI, JASON R. · 2022 to 2024
$747k
NCI NIH HHS P30 CA036727NCI NIH HHS R00 CA252153NCI NIH HHS R50 CA211462NCI NIH HHS U01 CA210240NIAID NIH HHS T32 AI095213NIDDK NIH HHS R01 DK130852NIGMS NIH HHS T32 GM135751
6 · The paper itself

Abstract

Pancreatic cancer patients have the highest rates and most severe forms of cancer cachexia, yet cachexia etiologies remain largely elusive, leading to a lack of effective intervening therapies. Parathyroid hormone-related protein (PTHrP) has been clinically implicated as a putative regulator of cachexia, with serum PTHrP levels correlating with increased weight loss in PDAC patients. Here we show that cachectic PDAC patients have high expression of tumor PTHrP and use a genetically engineered mouse model to functionally demonstrate that loss of PTHrP blocks cachectic wasting, dramatically extending overall survival. The re-expression of PTHrP in lowly cachectic models is sufficient to induce wasting and reduce survival in mice, which is reversed by the conditional deletion of the PTHrP receptor,

Indexed as

adipose wastingcancer cachexiade novo lipogenesisDNLPancreatic cancerPTHLHPTHrP

Identifiers

PMID40501563
PMCPMC12157458

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.